IL1A and cardiovascular disorder: At present, three biological inhibitors of IL-1 have been approved for treatment of rheumatoid arthritis and autoinflammatory diseases with promising results for cardiovascular disorders as well: anakinra, a recombinant molecule of the natural inhibitor IL-1 receptor antagonist; canakinumab, a humanized monoclonal antibody neutralizing human IL-1β; and rilonacept, a soluble chimeric Fc fusion protein of IL-1R1 and IL-1R3, able to inhibit the response to both IL-1α and IL-1β [65].